Drug Type Recombinant polypeptide, Biosimilar |
Synonyms 吉优泰, 吉可亲 |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | NDA/BLA | CN | 03 Apr 2024 | |
Obesity | Phase 3 | CN | 21 Oct 2024 | |
Cardiovascular Diseases | Phase 3 | CN | 25 Jul 2022 |